| Título: | Safranal Treatment Improves Hyperglycemia, Hyperlipidemia and Oxidative Stress in Streptozotocin-Induced Diabetic Rats |
| Autores: |
Samarghandian, Saeed; Department of Basic Medical Sciences, Neyshabur University of Medical Sciences, Neyshabur, Iran.
Health Strategic Research Center, Neyshabur University of Medical Sciences, Neyshabur, Iran. Borji, Abasalt; Department of Basic Medical Sciences, Neyshabur University of Medical Sciences, Neyshabur, Iran. Health Strategic Research Center, Neyshabur University of Medical Sciences, Neyshabur, Iran. Delkhosh, Mohammad Bagher; Health Strategic Research Center, Neyshabur University of Medical Sciences, Neyshabur, Iran. Samini, Fariborz; Neurosurgery Department, Faculty of Science, Mashhad University of Medical Sciences, Mashhad, Iran. |
| Fecha: | 2013-08-08 |
| Publicador: | Journal of Pharmacy and Pharmaceutical Sciences |
| Fuente: |
 |
| Tipo: |
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion |
| Tema: | No aplica |
| Descripción: | Purpose. Clinical research has confirmed the efficacy of several plant extracts in the modulation of oxidative stress associated with diabetes mellitus. Findings indicate that safranal has antioxidant properties. The aim of the present study was the evaluation of possible protective effects of safranal against oxidative damage in diabetic rats. Methods. In this study, the rats were divided into the following groups of 8 animals each: control, untreated diabetic, three safranal (0.25, 0.50, 0.75 mg/kg/day)-treated diabetic groups. Diabetes was induced by streptozotocin (STZ) in rats. STZ was injected intraperitoneally at a single dose of 60 mg/kg for diabetes induction. Safranal (intraperitoneal injection) was administered 3 days after STZ administration; these injections were continued to the end of the study (4 weeks). At the end of the 4-week period, blood was drawn for biochemical assays. In order to determine the changes of cellular antioxidant defense systems, antioxidant enzymes including glutathione peroxidase (GSHPx), superoxide dismutase (SOD) and catalase (CAT) activities were measured in serum. Moreover we also measured serum nitric oxide (NO) and serum malondialdehyde (MDA) levels, a marker of lipid peroxidation. Results. STZ-induced diabetes caused an elevation (p < 0.001) of blood glucose, MDA, NO, total lipids, triglycerides and cholesterol, with reduction of GSH level and CAT and SOD activities. The results indicated that the significant elevation in the blood glucose, MDA, NO, total lipids, triglycerides, cholesterol and reduction of glutathione level and CAT and SOD activity were ameliorated in the safranal–treated diabetic groups compared with the untreated groups, in a dose dependent manner (p < 0.05, p<0.01, p < 0.001). Conclusion. These results suggest that safranal has antioxidant properties and improves chemically-induced diabetes and its complications by modulation of oxidative stress. This article is open to POST-PUBLICATION REVIEW. Registered readers (see “For Readers”) may comment by clicking on ABSTRACT on the issue’s contents page. |
| Idioma: | Inglés |
1 The Impact of Electronic Prescribing on the Professionalization of Community Pharmacists: A Qualitative Study of Pharmacists’ Perception por Motulsky, Aude; Université de Montréal,Winslade, Nancy; McGill University,Tamblyn, Robyn; McGill University,Sicotte, Claude; Université de Montréal | 6 Effect of Inflammation on Molecular Targets and Drug Transporters por Hanafy, Sherif; Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton, Alberta, Canada,El-Kadi, Ayman O.S.,Jamali, Fakhreddin; Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton, Alberta, Canada |
2 Statins Against Drug-Induced Nephrotoxicity por Dashti-Khavidaki, Simin; Tehran University of Medical Sciences,Moghaddas, Azadeh; Tehran University of Medical Sciences,,Heydari, Behrooz; Tehran University of Medical Sciences,,Khalili, Hossein; Tehran University of Medical Sciences,lessan-Pezeshki, Mahboob; Tehran University of Medical Sciences,,Lessan-Pezeshki, Mahbooh; Tehran University of Medical Sciences | 7 |
3 Hepatotoxic Botanicals - An Evidence-based Systematic Review por Abdualmjid, Reem J; University of Alberta,Sergi, Consolato; University of Alberta | 8 |
4 The Decrease in Farnesoid X Receptor, Pregnane X Receptor and Constitutive Androstane Receptor in the Liver after Intestinal Ischemia-Reperfusion por Ogura, Jiro,Terada, Yusuke,Tsujimoto, Takashi,Koizumi, Takahiro,Kuwayama, Kaori,Maruyama, Hajime,Fujikawa, Asuka,Takaya, Atsushi,Kobayashi, Masaki,Itagaki, Shirou,Takahashi, Natsuko,Hirano, Takeshi,Yamaguchi, Hiroaki,Iseki, Ken | 9 Functional Food and Nutraceutical Registration Processes in Japan and China: A Diffusion of Innovation Perspective por Patel, Darshika; University of Auckland,Dufour, Yvon; University of Auckland,Domigan, Neil; Auctus Limited |
5 HPLC Analysis of Mesembrine-Type Alkaloids in Sceletium Plant Material Used as An African Traditional Medicine por Patnala, Srinivas; Rhodes University,Kanfer, Isadore; Faculty of Pharmacy, Rhodes University | 10 Inhibition of Human Cytochrome P450 Metabolism by Blended Herbal Products and Vitamins por Tam, Teresa W; Centre for Research in Biopharmaceuticals and Biotechnology, University of Ottawa, Ottawa, ON,Akhtar, Humayoun; Guelph Food Research Centre, Agriculture and Agri-Food Canada, Guelph, ON,Arnason, John Thor; Centre for Research in Biopharmaceuticals and Biotechnology, University of Ottawa, Ottawa, ON,Cvijovic, Kosta; Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, ON,Boon, Heather; Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, ON,Cameron, D William; Faculty of Medicine, Univeristy of Ottawa, Ottawa, ON,Drouin, Cathy E; Centre for Research in Biopharmaceuticals and Biotechnology, University of Ottawa, Ottawa, ON,Jaeger, Walter; Department of Clinical Pharmacy and Diagnostics, University of Vienna, Vienna,Tsuyuki, Ross T; Faculty of Medicine and Dentistry, University of Alberta, Edmonton, AB,Vohra, Sunita; CARE Program, Faculty of Medicine and School of Public Health, University of Alberta, Edmonton, AB,Foster, Brian C; Office of Science, Therapeutic Products Directorate, Health Canada, Ottawa, ON |